XL Del(20q)

Deletion Probe

Order Number
Package Size
100 µl


XL Del(20q)

This product has been replaced by XL Del(20q). Order Number D-5119-100-OG

Clinical Details

The myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008) cytogenetic aberrations are observed in about 50 % of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

A chromosome 20q deletion is associated with about 5 % of primary MDS. The majority of cases have an interstitial deletion between 20q11.2 and q13.3. As a single anomaly, the del(20q) has a favorable prognosis.

Clinical Applications

  • Myelodysplastic Syndrome (MDS)
  • Acute Myelogenous Leukemia (AML)


XL Del(20q)

XL Del(20q) hybridized to lymphocytes. One normal Interphase and one normal partial metaphase are shown

Expected Patterns

Expected Pattern 1

Normal Cell:
Two green (2G) and two orange (2O) signals.

Expected Pattern 2

Aberrant Cell (typical results):
Two green (2G) and one orange (1O) signal, indicating a deletion of PTPRT at 20q12.

Expected Pattern 3

Aberrant Cell (typical results): One green (1G) and two orange (2O) signals, indicating a deletion of MYBL2 at 20q13.

Expected Pattern 4

Aberrant Cell (typical results): One green (1G) and one orange (1O) signal, indicating deletions of both loci, PTPRT at 20q12 and MYBL2 at 20q13.


  • Bench et al (2000) Oncogene 19:3902-3913
  • Wang et al (2000) Genomics 67:28-39
  • Saunders et al (2005) Cancer Genet Cytogen 156:154-157


Order Now or Request Assistance

Contact Us »

Contact MetaSystems directly or find your local MetaSystems partner.